RET-话题@MedSci

#RET#

170篇内容 | 3763人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1913936, encodeId=79c41913936ae, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Nature：突变导致相分离发生紊乱进而引起Rett综合征, objectType=article, longId=199138, objectId=db0f1991386a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db0f1991386a, replyNumber=0, likeNumber=76, createdTime=2021-06-12, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db0f1991386a, moduleTitle=Nature：突变导致相分离发生紊乱进而引起Rett综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db0f1991386a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913926, encodeId=0e881913926dd, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=晚期胃肠道间质瘤（GIST）患者的新希望！四线疗法Ripretinib获FDA批准, objectType=article, longId=194259, objectId=741619425993, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=741619425993, replyNumber=0, likeNumber=80, createdTime=2020-11-09, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=741619425993, moduleTitle=晚期胃肠道间质瘤（GIST）患者的新希望！四线疗法Ripretinib获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=741619425993)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913941, encodeId=a2e719139418e, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=FDA批准Gavreto（pralsetinib）治疗转移性RET融合阳性非小细胞肺癌, objectType=article, longId=200381, objectId=9ed320038179, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ed320038179, replyNumber=0, likeNumber=79, createdTime=2020-10-09, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ed320038179, moduleTitle=FDA批准Gavreto（pralsetinib）治疗转移性RET融合阳性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ed320038179)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913919, encodeId=168019139194c, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始, objectType=article, longId=185522, objectId=448618552283, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=448618552283, replyNumber=0, likeNumber=69, createdTime=2020-05-07, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=448618552283, moduleTitle=RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=448618552283)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913937, encodeId=0977191393e9a, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=NEJM：Selpercatinib用于RET突变甲状腺髓样癌的治疗, objectType=article, longId=199972, objectId=ffdb1999e20f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffdb1999e20f, replyNumber=0, likeNumber=61, createdTime=2021-05-29, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffdb1999e20f, moduleTitle=NEJM：Selpercatinib用于RET突变甲状腺髓样癌的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffdb1999e20f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913934, encodeId=318a1913934d0, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=罗氏与Blueprint达成17亿美元协议：合作开发RET抑制剂pralsetinib治疗肺癌和甲状腺癌, objectType=article, longId=197610, objectId=85f519e610f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85f519e610f2, replyNumber=0, likeNumber=93, createdTime=2021-02-24, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85f519e610f2, moduleTitle=罗氏与Blueprint达成17亿美元协议：合作开发RET抑制剂pralsetinib治疗肺癌和甲状腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85f519e610f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913910, encodeId=9d3e191391037, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=FDA扩大了AbbVie的Mavyret用于丙型肝炎的批准，将治疗时间缩短至八周, objectType=article, longId=180135, objectId=23d51801355a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23d51801355a, replyNumber=0, likeNumber=69, createdTime=2020-08-23, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23d51801355a, moduleTitle=FDA扩大了AbbVie的Mavyret用于丙型肝炎的批准，将治疗时间缩短至八周, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23d51801355a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913911, encodeId=a3751913911fa, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=2019 ESMO|ripretinib或可成为经重度治疗的GIST患者的标准治疗, objectType=article, longId=181107, objectId=b30018110e10, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b30018110e10, replyNumber=0, likeNumber=80, createdTime=2020-09-12, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b30018110e10, moduleTitle=2019 ESMO|ripretinib或可成为经重度治疗的GIST患者的标准治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b30018110e10)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913909, encodeId=a223191390908, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=J Gastroenterology：Barrett食管与结肠癌之间的关系, objectType=article, longId=179668, objectId=99191e9668bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99191e9668bd, replyNumber=0, likeNumber=61, createdTime=2020-03-31, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99191e9668bd, moduleTitle=J Gastroenterology：Barrett食管与结肠癌之间的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99191e9668bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913916, encodeId=fef4191391641, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=伴松果体囊肿的Mollaret脑膜炎一例, objectType=article, longId=185096, objectId=5fb2185096d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5fb2185096d2, replyNumber=0, likeNumber=97, createdTime=2020-03-04, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5fb2185096d2, moduleTitle=伴松果体囊肿的Mollaret脑膜炎一例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fb2185096d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913920, encodeId=a11a191392063, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Regeneron的garetosmab显着降低了肌肉骨化症（"石头人症"）患者的骨骼异常增生, objectType=article, longId=186028, objectId=8a7a18602841, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a7a18602841, replyNumber=0, likeNumber=47, createdTime=2020-04-01, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a7a18602841, moduleTitle=Regeneron的garetosmab显着降低了肌肉骨化症（"石头人症"）患者的骨骼异常增生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a7a18602841)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913930, encodeId=689a19139306a, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Gastroenterology：6种Barrett食管筛查模型准确性研究, objectType=article, longId=196686, objectId=d48e1966861d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d48e1966861d, replyNumber=0, likeNumber=101, createdTime=2020-07-28, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d48e1966861d, moduleTitle=Gastroenterology：6种Barrett食管筛查模型准确性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d48e1966861d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913907, encodeId=62be191390e18, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Xynomic Research Institute：一系列有效的RET激酶抑制剂已被成功设计, objectType=article, longId=177981, objectId=ed811e798192, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed811e798192, replyNumber=0, likeNumber=64, createdTime=2020-05-24, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed811e798192, moduleTitle=Xynomic Research Institute：一系列有效的RET激酶抑制剂已被成功设计, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed811e798192)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913914, encodeId=205e191391416, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=PureTech的新型口服制剂KarXT在治疗精神分裂症的II期临床中展现前景, objectType=article, longId=183284, objectId=b20218328463, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b20218328463, replyNumber=0, likeNumber=75, createdTime=2020-10-04, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b20218328463, moduleTitle=PureTech的新型口服制剂KarXT在治疗精神分裂症的II期临床中展现前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b20218328463)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913933, encodeId=8f9e191393389, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Eur Urol：保留Retzius的机器人辅助根治性前列腺切除术可持久地改善泌尿功能和生活质量且不会减弱肿瘤疗效 , objectType=article, longId=197098, objectId=16fe19e09858, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16fe19e09858, replyNumber=0, likeNumber=54, createdTime=2021-04-09, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16fe19e09858, moduleTitle=Eur Urol：保留Retzius的机器人辅助根治性前列腺切除术可持久地改善泌尿功能和生活质量且不会减弱肿瘤疗效 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16fe19e09858)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913913, encodeId=26b3191391370, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=高明教授：RET高选择性抑制剂Selpercatinib(LOXO-292)给甲状腺癌患者带来新希望, objectType=article, longId=181524, objectId=3d71181524a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d71181524a9, replyNumber=0, likeNumber=54, createdTime=2020-03-06, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d71181524a9, moduleTitle=高明教授：RET高选择性抑制剂Selpercatinib(LOXO-292)给甲状腺癌患者带来新希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d71181524a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913915, encodeId=f3a019139159e, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=J Gastroenterology：日本人群腹部内脏脂肪肥胖与长节段Barrett食管之间的关联, objectType=article, longId=183878, objectId=31101838e8ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31101838e8ec, replyNumber=0, likeNumber=57, createdTime=2020-08-04, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31101838e8ec, moduleTitle=J Gastroenterology：日本人群腹部内脏脂肪肥胖与长节段Barrett食管之间的关联, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31101838e8ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913921, encodeId=3e631913921aa, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Ripretinib治疗晚期胃肠道间质瘤取得NDA优先审查权, objectType=article, longId=188009, objectId=684e1880092a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=684e1880092a, replyNumber=0, likeNumber=59, createdTime=2020-04-20, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=684e1880092a, moduleTitle=Ripretinib治疗晚期胃肠道间质瘤取得NDA优先审查权, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=684e1880092a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913908, encodeId=ee9b191390883, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=2019 ASGE指南：Barrett''s食管的筛查和监测, objectType=article, longId=179113, objectId=3fb91e9113f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fb91e9113f2, replyNumber=0, likeNumber=32, createdTime=2020-03-05, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fb91e9113f2, moduleTitle=2019 ASGE指南：Barrett''s食管的筛查和监测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fb91e9113f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1913912, encodeId=e049191391261, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, objectTitle=Clinica Chimica Acta：基于荧光共振能量转移(FRET)半定量分析碳水化合物缺乏转铁蛋白(CDT)的低成本新方法, objectType=article, longId=181503, objectId=99e218150310, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99e218150310, replyNumber=0, likeNumber=59, createdTime=2020-05-26, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99e218150310, moduleTitle=Clinica Chimica Acta：基于荧光共振能量转移(FRET)半定量分析碳水化合物缺乏转铁蛋白(CDT)的低成本新方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99e218150310)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

RET

2020-05-29

ysjykql (审核中...)

前往app查看评论内容

#RET#

Nature：突变导致相分离发生紊乱进而引起Rett综合征

2021-06-12

ysjykql (审核中...)

前往app查看评论内容

#RET#

晚期胃肠道间质瘤（GIST）患者的新希望！四线疗法Ripretinib获FDA批准

2020-11-09

ysjykql (审核中...)

前往app查看评论内容

#RET#

FDA批准Gavreto（pralsetinib）治疗转移性RET融合阳性非小细胞肺癌

2020-10-09

ysjykql (审核中...)

前往app查看评论内容

#RET#

RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始

2020-05-07

ysjykql (审核中...)

前往app查看评论内容

#RET#

NEJM：Selpercatinib用于RET突变甲状腺髓样癌的治疗

2021-05-29

ysjykql (审核中...)

前往app查看评论内容

#RET#

罗氏与Blueprint达成17亿美元协议：合作开发RET抑制剂pralsetinib治疗肺癌和甲状腺癌

2021-02-24

ysjykql (审核中...)

前往app查看评论内容

#RET#

FDA扩大了AbbVie的Mavyret用于丙型肝炎的批准，将治疗时间缩短至八周

2020-08-23

ysjykql (审核中...)

前往app查看评论内容

#RET#

2019 ESMO|ripretinib或可成为经重度治疗的GIST患者的标准治疗

2020-09-12

ysjykql (审核中...)

前往app查看评论内容

#RET#

J Gastroenterology：Barrett食管与结肠癌之间的关系

2020-03-31

ysjykql (审核中...)

前往app查看评论内容

#RET#

伴松果体囊肿的Mollaret脑膜炎一例

2020-03-04

ysjykql (审核中...)

前往app查看评论内容

#RET#

Regeneron的garetosmab显着降低了肌肉骨化症（"石头人症"）患者的骨骼异常增生

2020-04-01

ysjykql (审核中...)

前往app查看评论内容

#RET#

Gastroenterology：6种Barrett食管筛查模型准确性研究

2020-07-28

ysjykql (审核中...)

前往app查看评论内容

#RET#

Xynomic Research Institute：一系列有效的RET激酶抑制剂已被成功设计

2020-05-24

ysjykql (审核中...)

前往app查看评论内容

#RET#

PureTech的新型口服制剂KarXT在治疗精神分裂症的II期临床中展现前景

2020-10-04

ysjykql (审核中...)

前往app查看评论内容

#RET#

Eur Urol：保留Retzius的机器人辅助根治性前列腺切除术可持久地改善泌尿功能和生活质量且不会减弱肿瘤疗效

2021-04-09

ysjykql (审核中...)

前往app查看评论内容

#RET#

高明教授：RET高选择性抑制剂Selpercatinib(LOXO-292)给甲状腺癌患者带来新希望

2020-03-06

ysjykql (审核中...)

前往app查看评论内容

#RET#

J Gastroenterology：日本人群腹部内脏脂肪肥胖与长节段Barrett食管之间的关联

2020-08-04

ysjykql (审核中...)

前往app查看评论内容

#RET#

Ripretinib治疗晚期胃肠道间质瘤取得NDA优先审查权

2020-04-20

ysjykql (审核中...)

前往app查看评论内容

#RET#

2019 ASGE指南：Barrett''s食管的筛查和监测

2020-03-05

ysjykql (审核中...)

前往app查看评论内容

#RET#

Clinica Chimica Acta：基于荧光共振能量转移(FRET)半定量分析碳水化合物缺乏转铁蛋白(CDT)的低成本新方法

2020-05-26

科室
- - 订阅+
  - 更多科室
工具
服务